Introduction
Most regulatory affairs career conversations orbit around drugs, biologics, and medical devices. A narrower, less-discussed category sits at the intersection of food and drug regulation: infant formula and medical foods. It is a small professional community compared to mainstream pharmaceutical or device regulatory affairs, but it has drawn more attention and more hiring activity in recent years, particularly after the well-documented 2022 US infant formula shortage put a spotlight on how thin the regulatory and manufacturing resilience in this space actually was.
This article explains what makes infant formula and medical food regulation its own distinct lane, what the day-to-day work looks like, who is hiring, and whether it is worth treating as a deliberate career niche rather than a detour.
Two Different Regulatory Categories, Often Confused
Infant formula and medical foods are frequently lumped together with dietary supplements or conventional food in casual conversation, but each sits under its own distinct part of the regulatory framework, and the distinctions matter for anyone doing the actual work.
In the United States, infant formula is regulated by FDA under specific statutory provisions of the Federal Food, Drug, and Cosmetic Act, with detailed implementing regulations covering nutrient specifications, required quality control procedures, testing for nutrients and pathogens, and premarket notification requirements before a new formula or a reformulation can be marketed. Medical foods — products formulated for the dietary management of a specific disease or condition under physician supervision, such as formulas for inherited metabolic disorders like phenylketonuria — are also FDA-regulated, but under a different statutory framework than either conventional drugs or infant formula, and they do not go through a premarket drug approval process. Both categories are distinct again from dietary supplements, which fall under yet another part of the regulatory structure. The European Union has a broadly analogous but legally distinct category, food for special medical purposes (FSMP), regulated separately from pharmaceuticals.
None of this overlaps cleanly with the drug or device regulatory pathways most regulatory affairs professionals train on, which is exactly why it functions as its own niche rather than a simple subset of pharmaceutical regulatory affairs.
Why This Space Needed More Regulatory Attention
The 2022 US infant formula shortage, triggered by a major manufacturing shutdown and associated contamination concerns, is a matter of public record and widely reported at the time. It exposed just how concentrated domestic formula manufacturing capacity was, and it pushed FDA and industry toward greater focus on supply resilience, including pathways for temporarily easing import requirements for overseas manufacturers seeking to enter the US market under enforcement discretion. The specifics of any individual agency initiative since then are worth verifying directly with FDA's own published guidance rather than assumed, since policy in this area has continued to evolve. What is safe to say in general terms is that the episode drew sustained attention to a corner of food-drug regulatory law that previously ran with relatively little outside scrutiny, and that attention has translated into more regulatory affairs hiring need than this niche saw a decade ago.
What the Work Actually Looks Like
Regulatory affairs professionals in this space spend time on work that looks procedurally similar to pharmaceutical regulatory affairs but runs through a different rulebook. That includes compiling and submitting required premarket notifications for new formulas or significant reformulations, coordinating with quality teams on the testing panels formula manufacturers are required to run, reviewing labeling for required nutrient and use statements, interfacing with FDA's nutrition and food labeling functions rather than a drug review division, and for international manufacturers, managing the import-entry and facility-registration requirements that come with entering the US market. Staying current on FDA guidance updates specific to infant formula and medical foods is also a real and ongoing part of the job, since this is a narrower guidance landscape than pharmaceutical regulatory affairs and updates can shift expectations meaningfully.
Who Is Hiring
Demand comes from a few distinct directions: established infant formula manufacturers maintaining existing product lines and managing ongoing compliance; medical food and metabolic formula companies serving patients with inherited metabolic disorders, where the clinical stakes of getting labeling and formulation right are high; international manufacturers seeking to enter or expand in the US market, who often need regulatory affairs expertise specifically because the US framework differs from their home market's rules; and a smaller number of consulting firms building out a food-regulatory practice adjacent to their core life sciences work.
That last category deserves a closer look, because it is often the easiest entry point for someone without existing contacts inside an infant formula manufacturer. Consulting firms that serve this space tend to pull talent from both directions — people with food science or nutrition backgrounds who learn the regulatory side, and people with pharmaceutical or device regulatory affairs backgrounds who learn the food-law side — which makes it one of the more realistic ways to build a track record before moving in-house.
What an International Manufacturer's Entry Looks Like
One of the more distinctive pieces of work in this niche involves helping an overseas manufacturer bring a formula product into the US market, which became a more visible and more common project type in the aftermath of the 2022 shortage as FDA worked through pathways to ease short-term supply pressure. That work typically starts with a facility registration and a detailed gap analysis comparing the manufacturer's existing nutrient profile, quality control testing, and labeling against US requirements, since formulas built for other markets rarely match US nutrient specifications or labeling conventions exactly. From there, the regulatory affairs professional usually coordinates translation and reformatting of technical dossiers, works with the manufacturer's quality team to close any testing gaps, and manages the premarket notification process with FDA before product can be legally marketed. It is detailed, exacting work, closer in spirit to a technical due-diligence exercise than to a conventional regulatory submission, and it is also one of the clearest examples of where this niche rewards people who are comfortable holding two regulatory systems in their head at once.
How This Niche Differs From Pharma or Device Regulatory Work
The most important mental adjustment for someone coming from pharmaceutical or device regulatory affairs is that infant formula and medical foods do not go through anything resembling an NDA, BLA, or 510(k) premarket approval process. There is still real regulatory rigor — required testing, quality systems, labeling review, and premarket notification — but the legal foundation is food law under the FD&C Act's food provisions, not drug or device law. That means someone with deep pharma or device regulatory experience brings transferable skills (submission writing, quality system fluency, agency interaction) but still has a genuinely new rulebook to learn, not just a smaller version of a familiar one.
The professional community is also noticeably smaller than mainstream pharmaceutical or device regulatory affairs, which cuts both ways: fewer established mentors and fewer formal training pathways to lean on, but also less competition for roles and more visibility for people who do build deep expertise.
Is This a Good Entry Point or Pivot?
For someone with a food science, nutrition, or clinical nutrition background who wants life-science-adjacent regulatory work, this niche is a genuinely good fit and arguably underexplored. It can also work as a deliberate pivot for an early-career regulatory affairs professional, since there is less competition from candidates with deep prior expertise in this specific area compared to mainstream pharmaceutical regulatory affairs roles. The caution worth stating plainly: this is a narrow niche with meaningfully fewer total employers than mainstream pharma or device regulatory affairs. It is worth choosing deliberately, with a clear sense of the trade-off between a smaller but more open field and a far larger but more competitive one, rather than drifting into it by accident.
It is also worth being honest about the ceiling. Career paths within infant formula and medical food regulatory affairs tend to top out at a smaller number of senior roles than pharmaceutical regulatory affairs offers, simply because there are fewer companies in the space. Some professionals use it as a stable, interesting home for a full career; others use a few years here as a way to build submission and agency-interaction experience before moving into pharmaceutical or device regulatory affairs, where that foundational experience transfers more readily than people often expect. Either path is legitimate, and it is worth deciding early which one you are aiming for, since it changes how you think about building your network and your skill set while you are in the role. Talking to people already working in this niche, through RAPS's food and nutrition-adjacent interest groups or direct outreach to regulatory affairs professionals at infant formula and medical food companies on LinkedIn, is a reasonable first step before committing either way.
Conclusion
Infant formula and medical food regulatory affairs will never rival pharmaceutical or device regulatory affairs in total job volume, but it is a real, technically rigorous niche that has drawn more attention since 2022, and it rewards people willing to learn a rulebook most of the profession never looks at closely. For the right background and the right appetite for a smaller professional community, it is worth serious consideration rather than being treated as a footnote.